Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Rating) saw a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 118,100 shares, a decrease of 23.8% from the October 31st total of 154,900 shares. Based on an average trading volume of 78,300 shares, the days-to-cover ratio is presently 1.5 days. Approximately 1.2% of the company's stock are sold short.

Hedge Funds Weigh In On Bluejay Diagnostics

Several hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC acquired a new stake in shares of Bluejay Diagnostics during the 2nd quarter worth about $54,000. Virtu Financial LLC purchased a new stake in Bluejay Diagnostics in the second quarter valued at approximately $45,000. Finally, Millennium Management LLC acquired a new position in shares of Bluejay Diagnostics in the second quarter valued at approximately $27,000. Institutional investors and hedge funds own 1.21% of the company's stock.

Bluejay Diagnostics Stock Performance

Shares of BJDX stock traded up $0.03 during mid-day trading on Thursday, hitting $0.68. 10,980 shares of the stock traded hands, compared to its average volume of 59,734. The stock's fifty day moving average is $0.78 and its two-hundred day moving average is $0.98. Bluejay Diagnostics has a 52-week low of $0.61 and a 52-week high of $3.59.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc, a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components.

Recommended Stories

• Get a free copy of the StockNews.com research report on Bluejay Diagnostics (BJDX)
• Are the Short Sellers Still Right About Mullen Automotive stock?
• La-Z-Boy Reclines To More Comfortable Levels
• Is Apple Going To Rally Into Year End?
• Is The Recovery Rally Here For SoFi?
• Will Easing Of Covid Rules Slash Risk For Chinese EV Maker NIO?

Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.